YTENQ (Yield10 Bioscience) Cyclically Adjusted Revenue per Share: $ (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

YTENQ Yield10 Bioscience Inc YTENQ
16 GF Score
Price $0.00
View Full Analysis

What is Yield10 Bioscience Cyclically Adjusted Revenue per Share?

Yield10 Bioscience YTENQ 16 Cyclically Adjusted Revenue per Share is $ as of Jun. 2024. GuruFocus rates YTENQ with a GF Score™ of 16/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Yield10 Bioscience's adjusted revenue per share for the three months ended in Jun. 2024 was $0.700. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $ for the trailing ten years ended in Jun. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-21), Yield10 Bioscience's current stock price is $0.0001. Yield10 Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was $. Yield10 Bioscience's Cyclically Adjusted PS Ratio of today is .


Yield10 Bioscience  (OTCPK:YTENQ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Yield10 Bioscience Cyclically Adjusted Revenue per Share Related Terms


Yield10 Bioscience Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Yield10 Bioscience's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yield10 Bioscience Cyclically Adjusted Revenue per Share Chart

Yield10 Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Yield10 Bioscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

YTENQ vs GNVR, CTVA, CF: Cyclically Adjusted Revenue per Share Comparison

For the Agricultural Inputs subindustry, Yield10 Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yield10 Bioscience Cyclically Adjusted PS Ratio vs Agriculture Industry

For the Agriculture industry and Basic Materials sector, Yield10 Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Yield10 Bioscience's Cyclically Adjusted PS Ratio falls into.


YTENQ
16GF Score
Yield10 Bioscience Inc YTENQ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yield10 Bioscience Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Yield10 Bioscience's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.7/314.1750*314.1750
=0.700

Current CPI (Jun. 2024) = 314.1750.

Yield10 Bioscience Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 646.730 238.031 853.613
201412 414.789 234.812 554.982
201503 274.512 236.119 365.260
201506 308.960 238.638 406.756
201509 116.355 237.945 153.631
201512 35.514 236.525 47.173
201603 55.073 238.132 72.660
201606 651.144 241.018 848.788
201609 162.933 241.428 212.028
201612 115.724 241.432 150.591
201703 109.522 243.801 141.136
201706 98.727 244.955 126.626
201709 62.764 246.819 79.892
201712 24.712 246.524 31.493
201803 5.939 249.554 7.477
201806 27.383 251.989 34.141
201809 7.288 252.439 9.070
201812 12.927 251.233 16.166
201903 11.334 254.202 14.008
201906 24.433 256.143 29.969
201909 17.177 256.759 21.018
201912 5.903 256.974 7.217
202003 2.531 258.115 3.081
202006 2.709 257.797 3.301
202009 1.964 260.280 2.371
202012 1.404 260.474 1.693
202103 1.095 264.877 1.299
202106 0.858 271.696 0.992
202109 0.453 274.310 0.519
202112 0.747 278.802 0.842
202203 0.731 287.504 0.799
202206 0.504 296.311 0.534
202209 0.541 296.808 0.573
202212 0.422 296.797 0.447
202303 0.288 301.836 0.300
202306 0.000 305.109 0.000
202309 0.000 307.789 0.000
202312 0.000 306.746 0.000
202403 0.579 312.332 0.582
202406 0.700 314.175 0.700

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $ mean?
Yield10 Bioscience (YTENQ) has a Cyclically Adjusted Revenue per Share of $ as of Jun. 2024. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Yield10 Bioscience and its competitors.
Is Yield10 Bioscience's Cyclically Adjusted Revenue per Share too high?
Yield10 Bioscience's current Cyclically Adjusted Revenue per Share is $. Overall, Yield10 Bioscience has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Yield10 Bioscience's Cyclically Adjusted Revenue per Share compare to GNVR and CTVA?
Yield10 Bioscience's Cyclically Adjusted Revenue per Share of $ can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for an Agriculture company?
A good Cyclically Adjusted Revenue per Share depends on the Agriculture industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Yield10 Bioscience and its competitors. Yield10 Bioscience's current Cyclically Adjusted Revenue per Share is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yield10 Bioscience stock overvalued right now?
Yield10 Bioscience (YTENQ) has a current Cyclically Adjusted Revenue per Share of $. The current Cyclically Adjusted Revenue per Share is $. Yield10 Bioscience's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Yield10 Bioscience (YTENQ), the current Cyclically Adjusted Revenue per Share is $ as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yield10 Bioscience Business Description

Address 19 Presidential Way, Woburn, MA, USA, 01801
Yield10 Bioscience Inc is an agricultural bioscience company. It is leveraging advanced genetics to develop the oilseed Camelina sativa as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and, in the future, PHA bioplastics for use as biodegradable bioplastics.
16GF Score

Get the complete analysis for YTENQ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price